D-0101-2023 Class II Terminated

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0101-2023 was initiated by Direct Rx on Nov 2, 2022 and is designated Class II. Reason for recall: cGMP deviation: discontinue of stability support for product. The recall status is terminated (terminated Sep 30, 2024). Affected quantity: 11 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 18, 2023
Initiation Date
Nov 2, 2022
Termination Date
Sep 30, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11 bottles

Product description

Moxifloxacin Ophthalmic Solution, 0.5%, 3 mL, Rx Only, Packaged and Distributed By: Direct Rx, LLC 94 Worldwide Drive, Dawsonville, GA 30534, NDC 72189-0334-05

Reason for recall

cGMP deviation: discontinue of stability support for product.

Distribution pattern

FL

Code information

Lot #: 07MA2232, Exp. 4/30/23

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0101-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0101-2023. Report a data issue: hello@regdatalab.com.